The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy.
 
Christian Diego Rolfo
Consulting or Advisory Role - Mylan
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Guardant Health; MSD; Novartis
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Biomark (Inst); OncoDNA
 
Soren Bentzen
No Relationships to Disclose
 
Martin Devenport
Employment - OncoImmune
Leadership - OncoImmune
Stock and Other Ownership Interests - OncoImmune
Patents, Royalties, Other Intellectual Property - OncoImmune
Travel, Accommodations, Expenses - OncoImmune
 
Yang Liu
Employment - OncoImmune
Leadership - OncoImmune
Stock and Other Ownership Interests - OncoImmune
Research Funding - OncoImmune
Patents, Royalties, Other Intellectual Property - OncoImmune
Travel, Accommodations, Expenses - OncoImmune
 
Pan Zheng
Employment - OncoImmune
Leadership - OncoImmune
Stock and Other Ownership Interests - OncoImmune
Research Funding - OncoImmune
Patents, Royalties, Other Intellectual Property - OncoImmune
Travel, Accommodations, Expenses - OncoImmune